Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDEKUSU KK
Original Assignee
MEDEKUSU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDEKUSU KKfiledCriticalMEDEKUSU KK
Priority to JP11849283ApriorityCriticalpatent/JPS6011430A/ja
Publication of JPS6011430ApublicationCriticalpatent/JPS6011430A/ja
Publication of JPH034045B2publicationCriticalpatent/JPH034045B2/ja
Renset human-makrofag-migrationsinhiberingsfaktor (human-MIF) og dens enkeltproteiner, fremgangsmådetil fremstilling deraf, monoklonale antistoffer mod human-MIF og fremgangsmåde til den fremstilling,hybridomacellelinier, der producerer monoklonale antistoffer mod human-MIF, deres anvendelse og fremgangsmåde til deres fremstilling samt farmaceutiske præparater indeholdende renset human-MIF eller
α2-Macroglobulin, the main serum antiprotease, binds β2-microglobulin, the light chain of the class I major histocompatibility complex, which is involved in human disease
Solubilization of immune complex deposits by native 7S IgG molecules in lupus glomerulonephritis--a possible antigen excess effect on rheumatoid factor-IgG complexes